Literature DB >> 16333125

Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.

Loredana Sarmati1, Saverio Giuseppe Parisi, Emanuele Nicastri, Gabriella d'Ettorre, Lucia Palmisano, Mauro Andreotti, Carolina Andreoni, Marina Giuliano, Francesca Gatti, Caterina Boldrin, Giorgio Palù, Vincenzo Vullo, Stefano Vella, Massimo Andreoni.   

Abstract

The association between human immunodeficiency virus (HIV) DNA load and immunologic parameters was investigated in 163 HIV-infected patients with undetectable plasma viremia during highly active antiretroviral therapy (HAART). Patients with HIV DNA below the 25th percentile (133 copies/10(6) peripheral blood mononuclear cells) had higher pre-HAART (P = 0.001) and current (P = 0.005) CD4 counts and a prolonged duration of treatment (P = 0.001). At adjusted analysis, prolonged duration of treatment was independently associated with lower (P = 0.006) and undetectable (P < 0.001) HIV DNA values.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16333125      PMCID： PMC1317166          DOI： 10.1128/JCM.43.12.6183-6185.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy.

Authors:  Isabelle Pellegrin; Anne Caumont; Isabelle Garrigue; Patrick Merel; Marie-Hélène Schrive; Hervé Fleury; Michel Dupon; Jean-Luc Pellegrin; Jean-Marie Ragnaud
Journal:  J Infect Dis       Date:  2002-12-13       Impact factor: 5.226

2.  Biphasic decay of cell-associated HIV-1 DNA in HIV-1-infected children on antiretroviral therapy.

Authors:  Anita De Rossi; A Sarah Walker; Davide De Forni; Diana M Gibb
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

3.  Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.

Authors:  Jean-Paul Viard; Marianne Burgard; Jean-Baptiste Hubert; Laurent Aaron; Cécile Rabian; Nathalie Pertuiset; Maria Lourenço; Chantal Rothschild; Christine Rouzioux
Journal:  AIDS       Date:  2004-01-02       Impact factor: 4.177

4.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.

Authors:  T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

5.  Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection.

Authors:  S Yerly; T V Perneger; S Vora; B Hirschel; L Perrin
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

6.  Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.

Authors:  N Ngo-Giang-Huong; C Deveau; I Da Silva; I Pellegrin; A Venet; M Harzic; M Sinet; J F Delfraissy; L Meyer; C Goujard; C Rouzioux
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

7.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

9.  Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.

Authors:  Camlin Tierney; Janet L Lathey; Cindy Christopherson; Daniel M Bettendorf; Richard T D'Aquila; Scott M Hammer; David A Katzenstein
Journal:  J Infect Dis       Date:  2002-12-13       Impact factor: 5.226

10.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy.

Authors:  M E Sharkey; I Teo; T Greenough; N Sharova; K Luzuriaga; J L Sullivan; R P Bucy; L G Kostrikis; A Haase; C Veryard; R E Davaro; S H Cheeseman; J S Daly; C Bova; R T Ellison; B Mady; K K Lai; G Moyle; M Nelson; B Gazzard; S Shaunak; M Stevenson
Journal:  Nat Med       Date:  2000-01       Impact factor: 87.241
View more
  8 in total

Review 1.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1-HCV co-infected patients on effective combined anti-HIV treatment.

Authors:  Saverio G Parisi; Samantha Andreis; Carlo Mengoli; Nicola Menegotto; Silvia Cavinato; Renzo Scaggiante; Massimo Andreoni; Giorgio Palù; Monica Basso; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2018-03-09       Impact factor: 3.402

3.  Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy.

Authors:  Saverio Giuseppe Parisi; Samantha Andreis; Carlo Mengoli; Renzo Scaggiante; Roberto Ferretto; Vinicio Manfrin; Mario Cruciani; Mario Giobbia; Caterina Boldrin; Monica Basso; Massimo Andreoni; Giorgio Palù; Loredana Sarmati
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

4.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

5.  Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.

Authors:  Dai Watanabe; Shiro Ibe; Tomoko Uehira; Rumi Minami; Atsushi Sasakawa; Keishiro Yajima; Hitoshi Yonemoto; Hiroki Bando; Yoshihiko Ogawa; Tomohiro Taniguchi; Daisuke Kasai; Yasuharu Nishida; Masahiro Yamamoto; Tsuguhiro Kaneda; Takuma Shirasaka
Journal:  BMC Infect Dis       Date:  2011-05-24       Impact factor: 3.090

6.  Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.

Authors:  Saverio Giuseppe Parisi; Monica Basso; Carlo Mengoli; Renzo Scaggiante; Samantha Andreis; Marzia Maria Franzetti; Anna Maria Cattelan; Daniela Zago; Mario Cruciani; Massimo Andreoni; Sara Piovesan; Giorgio Palù; Alfredo Alberti
Journal:  Ann Gastroenterol       Date:  2017-07-04

7.  Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach.

Authors:  Carlo Mengoli; Monica Basso; Samantha Andreis; Renzo Scaggiante; Mario Cruciani; Roberto Ferretto; Sandro Panese; Vinicio Manfrin; Daniela Francisci; Elisabetta Schiaroli; Gaetano Maffongelli; Loredana Sarmati; Massimo Andreoni; Franco Baldelli; Giorgio Palu'; Saverio Giuseppe Parisi
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

8.  A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study.

Authors:  Yongsong Yue; Nidan Wang; Yang Han; Ting Zhu; Jing Xie; Zhifeng Qiu; Xiaojing Song; Yanling Li; Jean-Pierre Routy; Jianhua Wang; Taisheng Li
Journal:  BMC Infect Dis       Date:  2017-12-15       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.